<DOC>
	<DOCNO>NCT00424047</DOCNO>
	<brief_summary>The study compare efficacy oral lenalidomide combination oral pulse high-dose dexamethasone placebo oral high-dose pulse dexamethasone treatment participant relapse refractory multiple myeloma .</brief_summary>
	<brief_title>A Study Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone Previously Treated Patients With Multiple Myeloma</brief_title>
	<detailed_description>The study initiate 2003 enrol total 351 participant . The study unblinded start 03 August 2005 preplanned interim analysis demonstrate highly significant treatment benefit favor lenalidomide/dexamethasone combination base result primary endpoint , time progression ( TTP ) . In March 2008 , specify number least 194 death event need full statistical power overall survival ( OS ) analysis reach . At time 02 March 2008 cutoff date , still 29 participant active treatment Europe ( Austria , Belgium , France , Italy , Poland , Spain Ukraine ) Israel . Only safety data collect participant beyond 02 March 2008 cutoff date . The last visit last patient occur 25 June 2013 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Prior current diagnosis DurieSalmon stage II III multiple myeloma . Measurable level myeloma paraprotein serum urine ( 24hour collection sample ) . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0,1 , 2 Females childbearing potential must negative serum urine pregnancy test within 7 day start study drug Prior development disease progression highdose dexamethasone contain therapy Pregnant lactating females The development desquamate rash take thalidomide Use standard/experimental antimyeloma therapy within 28 day randomization use experimental nondrug therapy within 56 day initiation drug treatment Laboratory abnormality : Absolute neutrophil count less 1,000 cells/mm^3 Laboratory abnormality : Platelet count &lt; 75,000/mm^3 Laboratory abnormality : Serum creatinine &gt; 2.5 mg/dL Laboratory abnormality : Serum glutamic oxaloacetic transaminase ( SGOT ) /aspartate aminotransferase ( AST ) serum glutamic pyruvic transaminase ( SGPT ) /Alanine aminotransferase ( ALT ) &gt; 3.0 x upper limit normal Laboratory abnormality : Serum total bilirubin &gt; 2.0 mg/dL Prior history malignancy multiple myeloma unless subject free disease â‰¥ 3 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Celgene</keyword>
	<keyword>Revlimid</keyword>
	<keyword>CC-5013</keyword>
</DOC>